Literature DB >> 23678597

[Olanzapine].

Nobuhiro Nagai1, Koichiro Watanabe.   

Abstract

Olanzapine is one of the SGAs (second-generation antipsychotics) which have been used for the treatment of patients with schizophrenia and bipolar disorder in Japan. Olanzapine has various affinities for multiple receptors, including dopamine D2 receptor, serotonin 5-HT2A, 5-HT2C, 5-HT6 receptors, and adrenaline alpha1, histamine H1, muscarine M1-M5 receptors as well. Therefore, olanzapine is known as MARTA(multi-acting receptor targeted antipsychotics). Numerous studies have been conducted to compare the effectiveness of olanzapine between SGAs and FGAs (first-generation antipsychotics). According to the head-to-head meta-analysis and large-scale studies like CATIE and EUFEST, olanzapine seems to have not only higher efficacy but also less discontinuation comparing to other anti-psychotics.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23678597

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  3 in total

1.  Delusions of Glass Under Skin: An Unusual Case of Somatic-Type Delusional Disorder Treated with Olanzapine.

Authors:  Nicholas Comardelle; Amber Edinoff; Juliana Fort
Journal:  Health Psychol Res       Date:  2022-05-30

2.  1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia.

Authors:  Magdalena Białoń; Agnieszka Chocyk; Iwona Majcher-Maślanka; Marcelina Żarnowska; Krzysztof Michalski; Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik
Journal:  Pharmacol Rep       Date:  2021-01-06       Impact factor: 3.024

3.  Utilization of Polymeric Micelles as a Lucrative Platform for Efficient Brain Deposition of Olanzapine as an Antischizophrenic Drug via Intranasal Delivery.

Authors:  Hadel A Abo El-Enin; Marwa F Ahmed; Ibrahim A Naguib; Shaymaa W El-Far; Mohammed M Ghoneim; Izzeddin Alsalahat; Hend Mohamed Abdel-Bar
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.